Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

InMed Pharmaceuticals Inc INM

InMed Pharmaceuticals Inc. is a pharmaceutical company. It develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharmaceuticals segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is cannabinoid analog being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a cannabinol topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.


NDAQ:INM - Post by User

Post by Bullknit101on Jan 22, 2022 8:21am
209 Views
Post# 34346276

InMed Q2 Earnings

InMed Q2 Earnings The upcoming Q2 Earnings Report on 10 Feb will show initial sales revenues. I expect at least between $300k-$600k from CBC sales to start. CBT sales will be reflected next quarterly and then I would expected much higher revenue numbers. A 100kg batch alone @ 10-20K per kg = $1M -$2M. This is how all the plant touching MSOs started out. But imagine, InMed will be addressing not only the health and wellness market (short term) but also the pharma drug market for Big Pharma as well. It's been a long wait but 2022 might the turning point of revenues numbers show healthy growth. https://www.nasdaq.com/market-activity/stocks/inm/earnings?random=61ec00f076c07
<< Previous
Bullboard Posts
Next >>